mercaptopurine has been researched along with Cystic-Fibrosis* in 2 studies
1 review(s) available for mercaptopurine and Cystic-Fibrosis
| Article | Year |
|---|---|
The liver in pediatric gastrointestinal disease.
Hepatic involvement is often encountered in gastrointestinal (GI) diseases, in part because of the close anatomic and physiologic relations between the liver and GI tract. Drainage of the mesenteric blood supply to the portal vein permits absorbed and/or translocated nutrients, toxins, bacterial elements, cytokines, and immunocytes to gain hepatic access. Liver problems in digestive disorders may range from nonspecific hepatocellular enzyme elevations to significant pathologic processes that may progress to end-stage liver disease. Hepatobiliary manifestations of primary GI diseases in childhood and adolescence are not uncommon and include several well-described associations, such as sclerosing cholangitis with inflammatory bowel disease. Liver damage may also result from the effects of drugs used to treat GI diseases, for example, the hepatotoxicity of immunomodulatory therapies. This review highlights the important features of the hepatic and biliary abnormalities associated with 3 common pediatric GI conditions: inflammatory bowel disease, celiac disease, and cystic fibrosis. Topics: Adolescent; Antibodies, Monoclonal; Azathioprine; Celiac Disease; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cholagogues and Choleretics; Cholangitis, Sclerosing; Cystic Fibrosis; Humans; Infant; Inflammatory Bowel Diseases; Infliximab; Liver Diseases; Liver Function Tests; Mercaptopurine; Methotrexate; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid | 2014 |
1 other study(ies) available for mercaptopurine and Cystic-Fibrosis
| Article | Year |
|---|---|
Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis.
A 3 1/2 year old girl with cystic fibrosis who underwent successful treatment for acute lymphoblastic leukemia remains in complete remission 36 months after diagnosis. We also report high clearance rates of three antineoplastic agents in this patient. Drug doses were adjusted to achieve optimal systemic exposure. Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cystic Fibrosis; Cytarabine; Daunorubicin; Female; Humans; Mercaptopurine; Methotrexate; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Teniposide; Vincristine | 1994 |